China National Pharmaceutical Group Signs Import and Distribution Agreement with Pfizer for Nirmatrelvir/Ritonavir (Paxlovid®) in Mainland China

China Meheco announced on December 14 that the company has signed an agreement with Pfizer, Inc. to be responsible for the import and distribution of Pfizer’s COVID-19 treatment drug, Paxlovid (Nirmatrelvir Tablets/Ritonavir Tablets), in the Chinese market during the term of the agreement. The agreement was signed and became effective on December 14, 2022, Beijing Time, and will continue until November 30, 2023, unless terminated early in accordance with the terms of the agreement.